Abbott Upbeat About Its Devices

☞ | View the full content of this post. Exclusively available to ASQ Members.

Nearly two years removed from its largest corporate acquisition, Abbott Laboratories still sees plenty of room for growth in the portfolio of devices and intellectual property it bought through the $25 billion deal for Minnesota’s St. Jude Medical.

“St. Jude, in the course of our acquisition negotiations with them, continued to talk to us [about] the veracity of their pipeline and how good it was. And to be honest, they were right. And that’s proven,” Abbott

☞ | View the full content of this post. Exclusively available to ASQ Members.